• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Immunohistochemical Expression of Galectin-3 and Cytokeratin 19 in the Spectrum of Thyroid Neoplasms
【24h】

Immunohistochemical Expression of Galectin-3 and Cytokeratin 19 in the Spectrum of Thyroid Neoplasms

机译：Galectin-3和细胞角蛋白19在甲状腺肿瘤谱中的免疫组织化学表达

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In systemic malignancies, thyroid carcinoma represents only 1%, but it is the commonest endocrine malignancy with poor prognosis. Fine Needle Aspiration (FNA) is considered a requisite tool in providing a rational advent for the clinical management of these nodules. However, when solely based on cytopathological assessment, FNA leads to imprecise biopsy results in 10-20% of all cases. So, immunohistochemical markers, Galectin-3 (Gal-3) and Cytokeratin 19 (CK19) have received considerable attention as diagnostic marker for thyroid cancer.Aim: To study the expression of Gal-3 and CK19 in different thyroid neoplasms.Materials and Methods: This cross-sectional study was conducted at a tertiary care hospital from January 2019 to January 2021 on 120 cases. The thyroidectomy specimens received were fixed in 10% buffered formalin followed by gross examination. The paraffin embedded tissue blocks were subsequently stained for Hematoxylin and Eosin stain (H&E) followed by histopathological reporting. Qualitative immunohistochemical assessment of the marker Gal-3 and CK19 was performed on representative histologic sections of the thyroid neoplasms. Data were analysed using Graph Pad Instat 3.Results: The positive expression of Gal-3 was significantly more in malignant tumours (87.5%) than in benign (36.0%) (p-value<0.001). In Papillary Thyroid Carcinomas (PTC) and in Follicular Variant of Papillary Thyroid Carcinomas (FVPTC) expression of Gal-3 was notably higher than in Follicular Adenoma (FA) (p-value=0.01 and p-value=0.0001 respectively). Follicular Thyroid Carcinomas (FTC) had higher expression FA (p-value=0.003). In malignant tumours (71.8%), positive expression of CK19 was significantly more than benign tumours (24.0%) (p-value <0.001). Significant difference in expression of CK19 was seen between PTC and FTC (p-value=0.019). Between PTC and FA, differences in expression were significant (p-value <0.001). Significant difference in expression was also seen between FVPTC and FTC (p-value=0.032) as well as with FA (p-value=0.028).Conclusion: The most sensitive marker is Gal-3 for the diagnosis of thyroid malignancies. When combined with CK19, the specificity increases in identifying the thyroid cancers. More combination of markers together with Gal-3 and CK19 can be useful in the distinction between malignant and benign thyroid tumours because it is essential for further treatment and long-term management of the patient.
机译：在全身恶性肿瘤中，甲状腺癌仅占1％，但它是最常见的内分泌恶性肿瘤，预后差。细针抽吸（FNA）被认为是提供对这些结节临床管理的理性出现的必要工具。然而，当仅基于细胞病变评估时，FNA导致所有病例的10-20％的生物检查导致效果不精确。因此，免疫组织化学标志物，半乳糖素-3（GAL-3）和细胞角蛋白19（CK19）作为甲状腺癌的诊断标志物得到了相当大的关注。重要的：研究GAL-3和CK19在不同的甲状腺肿瘤中的表达。材料和方法：这项横断面研究于2019年1月至1月2021年在120例案件下进行。接收的甲状腺切除术样品在10％缓冲福尔马林中固定，然后进行总检验。随后染色石蜡包埋的组织块用于苏木精和曙红染色（H＆amp; e），然后染色组织病理学报告。在甲状腺肿瘤的代表性组织学部分进行标记GAL-3和CK19的定性免疫组织化学评估。使用曲线垫Instat进行分析数据3.结果：恶性肿瘤的阳性表达比良性肿瘤（87.5％）显着更多（36.0％）（p值<0.001）。在乳头状甲状腺癌（PTC）和乳头状甲状腺癌（FVPTC）的滤泡变体中，GAL-3的表达显着高于滤泡腺瘤（FA）（p值= 0.01和p值分别）。卵泡甲状腺癌（FTC）具有更高的表达FA（p值= 0.003）。在恶性肿瘤（71.8％）中，CK19的阳性表达显着大于良性肿瘤（24.0％）（p值<0.001）。在PTC和FTC之间观察到CK19表达的显着差异（P值= 0.019）。在PTC和FA之间，表达的差异很大（P值<0.001）。在FVPTC和FTC（P值= 0.032）以及FA（p值= 0.028）之间也可以看到表达的显着差异（p值= 0.028）。结论：最敏感的标志物是GAL-3，用于诊断甲状腺恶性肿瘤。与CK19结合时，特异性增加鉴定甲状腺癌。与GAL-3和CK19一起的更多组合可以在恶性和良性甲状腺肿瘤之间分化，因为对患者的进一步治疗和长期管理是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号